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Progressive Resistance Training in Head and Neck Cancer Patients
Undergoing Concomitant Chemoradiotherapy
Camilla K. Lonkvist, MD; Anders Vinther, PhD; Bo Zerahn, MD; Eva Rosenbom, RD;
Atul S. Deshmukh, PhD; Pernille Hojman, PhD; Julie Gehl, MD, DMSc
Objectives: Patients with head and neck squamous cell carcinoma undergoing concomitant chemoradiotherapy (CCRT)
frequently experience weight loss, especially loss of lean body mass (LBM), and reduced functional performance. This study
investigated whether a 12-week hospital-based progressive resistance training (PRT) program during CCRT is feasible in the
clinical setting before planning initiation of a larger randomized study which is the long-term goal.
Study design: Prospective pilot study.
Methods: Twelve patients receiving CCRT were planned to attend a 12-week PRT program. Primary endpoint was feasi-
bility measured as attendance to training sessions. Secondary endpoints included changes in functional performance, muscle
strength, and body composition measured by Dual-energy X-ray Absorptiometry (DXA) scans. Furthermore, sarcomeric pro-
tein content, pentose phosphate pathway (PPP) activity, and glycolysis were determined in muscle biopsies.
Results: Twelve patients with p16 positive oropharyngeal cancer were enrolled. The primary endpoint was met with 9
of the 12 patients completing at least 25 of 36 planned training sessions. The mean attendance rate was 77%. Functional per-
formance was maintained during the treatment period and increased during follow-up (p< 0.01). Strength was regained after
an initial dip during treatment, paralleling responses in LBM and sarcomeric protein content. LBM began to increase immedi-
ately after treatment. The PPP was upregulated after the treatment period, whilst glycolysis remained unchanged. No adverse
events were related to PRT and in questionnaires, patients emphasized the social and psychological benefits of attendance.
Conclusion: Progressive resistance training is feasible and safe during CCRT for head and neck cancer, and is associated
with high patient satisfaction.
Key Words: Head and neck cancer, progressive resistance training, exercise, body composition, lean body mass.
Level of Evidence: 2C.
INTRODUCTION
Patients with head and neck squamous cell carci-
noma (HNSCC) often experience unintentional weight
loss during concomitant chemoradiotherapy (CCRT).1–3
Studies have shown that up to 72% of this treatment-
related loss of body weight is due to loss of lean body
mass (LBM).1,4 which again is associated with decline of
functional performance,4 quality of life (QoL),5 as well as
increased morbidity and mortality.6–10 Loss of LBM and
body weight can occur even when caloric intake is suffi-
cient to meet energy demand,11 indicating a multifacto-
rial pathogenesis.
Epidemiologic studies show that in addition to
improving physical functioning, physical activity is asso-
ciated with reduced risk of several cancers12 and
reduced mortality.13,14 A direct effect of exercise sup-
pressing cancer growth has been shown in preclinical
studies, pointing to an exercise-dependent regulation of
tumor biology.15,16
Furthermore, studies indicate that chemotherapy
side effects may be ameliorated by exercise. In a preclin-
ical study using weekly cisplatin, exercise attenuated
treatment-induced weight loss and increased muscle
mass, compared with controls.17
In head and neck cancer patients, exercise trials
studying training intervention during radiotherapy or
CCRT are sparse but have been gaining ground and
some studies have been published whilst this study was
conducted.18–21 The trials all differ in type of interven-
tion, intensity, frequency, as well as outcome measures.
But across these studies, changes in muscle strength,
mobility, physical activity, fatigue, diet, and QoL end-
points in favor of the training intervention group are
reported.
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Resistance training is an efficient way of maintain-
ing or increasing muscle mass and the aim of this pilot
study was to test the feasibility of a 12-week PRT pro-
gram, as well as the entire study logistics with scans,
questionnaires, and controls in our clinic before launch-
ing a randomized trial with difference in LBM as pri-
mary outcome measure.
We hypothesized that although HNSCC patients
experience a large symptom-burden during treatment,
PRT would be a feasible intervention during CCRT. Sec-
ondary aims were to investigate whether PRT may ame-
liorate weight loss and loss of LBM, as well as maintain
muscle strength and functional performance in HNSCC
patients. The chosen setting was a single-arm interven-
tion study comprising hospital-based supervised PRT for
12 weeks during and immediately after CCRT for
patients with HNSCC.
MATERIALS AND METHODS
Study Design and Patients
The study was a single-center, prospective study regis-
tered at www.clinicaltrials.gov (NCT02068950), and approved
by the regional Ethics Committee (# H-3-2013-186) and the
Danish Data Protection Agency.
Inclusion criteria: 1) histologically verified primary
HNSCC with primary tumor in the nasal cavity, oral cavity,
pharynx, or larynx, stage III or IV, and candidate for CCRT
according to the Danish Head and Neck Cancer (DAHANCA)
group guidelines; 2) Eastern Cooperative Oncology Group
(ECOG) performance status (PS) 0–1; 3) age 18 years; and 4)
signed informed consent.
Exclusion criteria: 1) comorbidity potentially interfering
with attendance or test results; 2) tonsillectomy within a week
before inclusion; 3) psychological, social, or geographical condi-
tions that could influence protocol adherence; 4) diastolic blood
pressure <45 or >95, resting heart rate >100; 5) signs of ische-
mia on electrocardiogram; 6) insufficient bone marrow function
(i.e., hemoglobin <6 mmol/L, leukocytes <2.53109/L, or plate-
lets <503109/L); 7) pregnancy.
Twelve patients were planned to be enrolled. This number
was chosen in order to enhance fast accrual while not compro-
mising the interpretation of the primary endpoint. Primary end-
point was feasibility measured by participation in training
sessions as recorded by the supervising physiotherapist. The
pragmatic predetermined goal was that >50% of patients would
attend at least 25 of 36 training sessions. This corresponds to at
least twice weekly attendance, which is considered a minimum
frequency if the goal is maximizing muscle growth.22
Secondary endpoints were changes in functional perfor-
mance, muscle strength, body composition, adverse events, die-
tary intake, self-reported physical activity, and QoL as well as
investigation of biological samples.
Muscle biopsies were taken for proteomic analyses and
blood samples for further analysis as described below.
Evaluation time schedule is shown in Supplementary
Table S1.
Treatment
All patients received CCRT, 66–68 Gy, in 2 Gy fractions, 6
fractions/week, with concurrent nimorazole p.o. (1,200 mg/m2)23
before each fraction (1,000 mg/m2 for same-day second fraction-
ation), and weekly cisplatin (40 mg/m2, max 70 mg). Prophylac-
tic anti-emetics were administered perorally. Prednisolone:
100 mg before cisplatin (day 1), 50 mg twice day 2, 25 mg twice
day 3, and once day 4. Ondansetron: 16 mg day 1 (if body
weight >80 kg, then 24 mg) and domperidone 10–20 mg as
needed maximally thrice daily.
Physiological saline (1,500 ml) and 8 mmol magnesium
sulfate was co-administered with cisplatin. Magnesium 360 mg
twice daily p.o. was administered the 3 following days.
If needed, the patients received nasogastric tube feeding.
The standard of care in the unit is to offer nasogastric tube
feeding if weight loss exceeds approximately 5% from baseline
(treatment start). Routine Percutaneous Endoscopic Gastro-
stomy (PEG) is not considered standard of care at our unit.
Progressive Resistance Training Program
The progressive resistance training (PRT) program was
almost identical to the program used in the DAHANCA 25 tri-
als24 and the progression model was based on guidelines from
the American College of Sports Medicine (ACSM).25 Exercises
were performed in training machines (Technogym) and super-
vised by a physiotherapist. Patients performed 7 conventional
exercises involving the large muscle groups (abdominal
crunches, back extensions, chest press, low row, hamstring
curls, knee extensions, and leg press). Progression in intensity
was achieved by patients advancing from 2–3 sets and 15–8 rep-
etition maximum (RM), hence, starting with low load/high repe-
tition progressing to high load/fewer repetitions per set
(Supplementary Table S2). PRT started concurrently with
CCRT. Thirty-six sessions were planned over 12 weeks with ses-
sions thrice weekly, every other weekday to ensure optimal
recovery time. After training sessions, patients were offered a
meal and protein supplement (Nutridrink compact, Nutricia,
125 mL, 1260 kJ, 12 g protein). Patients trained at the physical
rehabilitation therapy facilities at the hospital. Training, tests,
meals, chemo-, and radiotherapy were scheduled conveniently
within the given time frame (Supplementary Table S1).
Functional Performance and Strength Tests
Tests were supervised by physiotherapists. Functional per-
formance was assessed by maximal stair climbing, 30-second
chair stand test, and 30-second arm curl test (respectively 3
and 4 kg for women and men). These accepted methods have
been used previously in cancer patients.24 Muscle strength and
power were evaluated with reliable and validated tests; the 1-
repetition maximum (1RM) test in the leg and chest press
machines and the Nottingham Power Rig testing maximal leg
extension power.26
Body Composition
Changes in total body mass (TBM), LBM, and fat mass
(FM) was measured using whole-body Dual-energy X-ray Absorp-
tiometry (DXA) (GE lunar iDXA, GE Healthcare Technologies,
Madison, Wisconsin, US), software version 14.10. DXA-scan is a
standard and validated method to assess body composition.27
Weight was measured weekly (digital scale) with partici-
pants in light clothing, without shoes.
Blood Samples
Standard blood samples, e.g., hematology, prior to each
chemotherapy treatment were taken according to schedule
(Supplementary Table S1).
Only 36 mL of additional blood for analysis were drawn
during the course of radiotherapy. From baseline until 13-
months follow-up maximally 336 mL of blood were drawn for
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explorative biological analyses. At week 3 and 8–12, blood sam-
ples were drawn both before and immediately after PRT.
Muscle Biopsies and Proteomic Evaluation
Muscle biopsies were collected from the vastus lateralis
muscle with a 5 mm Bergstrom biopsy cannula (Pelomi Medi-
cal) at baseline, after CCRT, and after the 12-week PRT pro-
gram under local anesthesia (lidocaine/epinephrine 20 mg/5 mg/
mL).
Mass spectrometry based proteome analysis of skeletal
muscle lysate was conducted. Muscle biopsies from the 4
patients with the greatest difference in LBM over the 12-week
training program were analyzed. Protein lysate containing 100
mg of proteins was processed on 30k filtration units using the
FASP protocol,28 and endoproteinase Lys-C and trypsin were
used for the digestion of proteins. Digested peptides were sepa-
rated on a reverse phase column (20 cm, 75 mm inner diameter)
packed with 1.8 mm C18 particles (Dr. Maisch GmbH,
Ammerbuch-Entringen, Germany) using a 3 h acetonitrile gra-
dient in 0.1% formic acid at a flow rate of 250 nL/min. The col-
umn was coupled to a Q Exactive mass spectrometer (Thermo
Fisher Scientific, Dreieich, Germany) via a nanoelectrospray
source (Proxeon Biosystems, now Thermo Fisher Scientific). The
Q Exactive was operated in data dependent mode with survey
scans acquired at a resolution of 60,000. From a survey scan,
the top 15 most abundant isotope patterns with charge m/z 2
were selected with an isolation window of 1.6 Th and frag-
mented by HCD with normalized collision energies of 27. The
maximum ion injection times for the survey scan and the MS/
MS scans were 20 ms and 25 ms, respectively. The mass spec-
trometry data was analyzed in MaxQuant environment (version
1.5.2.8).29 Proteins were identified by searching MS and MS/MS
data of peptides against a decoy version of the UniProtKB/
Swiss-Prot. Carbamidomethylation of cysteines was set as a
fixed modification. The initial allowed mass deviation of the
precursor ion was up to 6 ppm, and for the fragment masses up
to 20 ppm. The maximum false peptide discovery rate was
specified as 0.01. Protein concentrations (pmol/mg of proteins)
were calculated as previously described.30 For further analyses
baseline values were set to 1.0 and the following normalized
accordingly.
The muscle fiber characterization was determined based
on gene expression of the respective gene, i.e., type 1 fibers
(myosin heavy chain [MYH] 7 gene), type 2a (MYH2 gene), type
2x (MYH1 gene), and type 2b (MYH4 gene). Fiber types and the
thick and thin filament, M and Z-band values are presented as
median and quartiles of the comprised proteins, whilst for the
sarcomeric proteins the individual values as well as medians
are presented.
The metabolic pathways were assessed based on protein
expression of enzymes from the respective pathways. Hence,
glycolysis was assessed by expression of the following enzymes:
Hexokinase 1 (HK1 gene), glucose-6-phospate isomerase (GPI
gene), 3 phosphofructokinase (PFK) isoenzymes (PFKM, PFKL,
and PFKP genes), 2 aldolase isoenzymes (ALDOA and ALDOC
genes), triosephosphate isomerase 1 (TPI1 gene),
glyceraldehyde-3-phosphate dehydrogenase (GADPH gene),
phosphoglycerate kinase 1 (PGK1 gene), phosphoglycerate
mutase 2 (PGAM2 gene), 2 enolase isoenzymes (ENO1 and
ENO3 genes), and pyruvate kinase (PKM gene). The pentose
phosphate pathway (PPP) was assessed by expression of the fol-
lowing enzymes: 6-phosphogluconolactonase (PGLS gene), phos-
phogluconate dehydrogenase (PGD gene), transketolase (TKT
gene) and transaldolase 1 (TALDO1). The medians and upper
quartiles of the comprised enzymes for the respective pathway
are presented.
Adverse Events Reporting
Adverse events were monitored according to Common Ter-
minology Criteria for Adverse Events (CTCAE) v4.0.
Performance status was registered according to ECOG
scale, and pain using the Numeric Rating Scale (NRS) for pain,
consisting of 11 points from 0 (no pain) to 10 (worst pain
imaginable).31
Questionnaires
Quality of life questionnaires. QoL was measured by
The European Organization for Research and Treatment of
Cancer Quality of Life Questionnaire C30 and H&N35 (EORTC
QLQ-C30 and QLQ-H&N35). The EORTC QLQ-C30 and
H&N35 together consist of global health status, 5 functional
scales (physical, role, cognitive, emotional, and social function-
ing), 10 symptom scales, and 12 individual items.32 QoL ques-
tionnaires were not done at the end of CCRT, as QoL
measurements would be affected by treatment side effects at
this time point.
Diet. Energy intake was measured using diet diaries. Rest-
ing metabolic rate (RMR) was measured using the Mifflin-St.
Jeor equation.33 Total energy need in kilojoule (kJ) was measured
as: Energy need (kJ)5RMR x activity factor x 4.184. Activity fac-
tor was set at 1.3 in case of low physical activity, and 1.5 if high
physical activity (see below) and set at 1.3 after treatment for all.
Protein need was estimated as 18% of total energy need.
Physical activity. Physical activity during leisure time
and work was registered by questionnaire using 4 levels in each
category: Leisure time: 1) sedentary, 2) light physical activity 2–
4 hours a week, 3) light physical activity more than 4 hours a
week, 4) hard physical activity more than 4 hours a week. Work
time: 1) sedentary (e.g., office work), 2) light work (e.g., clerk or
teacher), 3) heavier work (e.g., nurse or postman), 4) hard physi-
cal work (e.g., concrete worker). Scores were added and dichoto-
mized at 4 (low physical activity) or 5 (high physical activity).
Questionnaires about the program and affiliation to
labor market. At the end of the 12-week PRT program patients
were asked to fill out a semi-structured questionnaire regarding
the intervention. Affiliation to labor market was registered.
Statistics
For all statistical analyses, SPSS (IBM Corporation,
Armonk, New York, US, https://www.ibm.com/us-en/market
place/spss-statistics) 22.0 was used. Descriptive analysis was
used for the primary endpoint as well as for all other analyses
unless stated otherwise. Mixed-model analyses were used to
examine differences in means in body composition and in physi-
cal tests between baseline and end of CCRT, after the 12-week
PRT, and at 13-month follow-up, respectively. Bonferroni-Holm
corrections were made to correct for multiple comparisons. In
general, data were normally distributed, tested with Shapiro-
Wilks test, hence, unless otherwise stated values are presented
as mean6 standard deviation (SD).
Spearman’s test was used to assess correlation between
self-reported physical activity and performance during tests, as
well as between baseline BMI and loss of, respectively, TBM,
LBM, and FM at 12 weeks. The latter is presented with Spear-
man’s rho and statistical significance.
Repeated measures mixed model analyses were used to
examine training progression which is presented as mean kg
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load at each of the seven exercises. Only attending patients’
data were included in the analyses.
Quality of life data was descriptive and analyzed according
to EORTC QLQ-C30 Scoring Manual34 and presented as
median with range, further statistical analyses were not
performed.
For all analyses an alpha level of 5% was chosen for statis-
tical significance.
RESULTS
Inclusion
From February 2014 to July 2014, 24 patients were
screened for eligibility. It should be noted that due to
capacity challenges in the radiotherapy department there
was a 5-week inclusion break. Five patients did not meet
inclusion criteria and 19 were informed about the pro-
gram. Six declined to participate and one was not included
due to dysregulated diabetes. Accordingly, 12 patients
(63%) were included. Though not an inclusion criterion,
all patients had p16 positive oropharyngeal cancer. Flow
diagram is seen in Supplementary Figure S1 and patients’
baseline characteristics are listed in Table I.
No patients withdrew from the study but 2 patients
went off study before the 5-month follow-up due to diagno-
sis of metastatic disease, respectively new primary cancer.
Hence, 10 patients completed 13 months of follow-up.
Feasibility
The primary endpoint was met as 75% of patients
completed at least 25 of 36 training sessions (Fig. 1).
Mean completion time for the program was 12.7 weeks
(range 11.7–13.7 weeks). Mean attendance rate during
treatment was 93% (range 67–100%), and overall atten-
dance during the 12-week program was 776 22% (range
36–100%). Main reason for not attending sessions was
treatment-related side effects. No adverse events were
deemed related to PRT.
Treatment Completion
All patients completed full-dose radiotherapy. Ten
patients received all 5 planned cisplatin treatments, and
2 patients received only 4 (one due to leukopenia and
one due to hearing loss).
Functional Performance and Muscle Strength
During CCRT, patients’ functional performance
remained unchanged. After the treatment period, func-
tional performance tended to increase continuously, and
at the 13-month follow-up number of arm curls and
chair stands had increased significantly compared to
baseline (p< 0.01 and p< 0.001, respectively) (Fig. 2 and
Supplementary Table S3). It should be noted, that 3
patients felt too weak to be tested immediately after the
treatment period (week 6).
Strength as measured by 1RM in chest press
decreased significantly (p<0.01) while strength mea-
sured in leg press machine remained unchanged, albeit
with a lower measured strength just after the CCRT.
Large differences were observed between males and
females (Fig. 2), whether these were statistically signifi-
cant differences was not investigated. After the treat-
ment period, strength tended to improve continuously,
though, never reaching statistical significance, e.g., 1RM
in leg press machine increased from a mean of 144.46
41.6 kg to a mean of 182.0663.2 kg (Fig. 2 and Supple-
mentary Table S3). Not surprisingly, muscle power, i.e.,
force produced per kg body mass, followed the same pat-
tern as muscle strength (Fig. 2E), though not changing
significantly from baseline at any time point.
Regarding training intensity (i.e., weight lifted),
patients were able to progress in all exercises except
chest presses during the 12-week program (p< 0.05)
(Fig. 2F).
Body Composition
All patients experienced weight loss during CCRT.
Measurements from the weekly weighing showed that
TABLE I.
Patient Baseline Characteristics.
Characteristics No. of patients (%)
Patients included 12
Age, median years (range) 56 (47–66)
Sex
male/female 7 (58%)/5 (42%)
Primary site
oropharynx/cancer of the tonsils 12 (100%)/6 (50%)
Tumor p16 status
positive/negative 12 (100%)/0 (0%)
Clinical stage
III/IVa 1 (8%)/11 (92%)
Performance status (ECOG scale)
0/1 12 (100%)/0 (%)
Smoking status
Never 3 (25%)
Former 7 (58%)
Current 2 (17%)
Level of physical activity at baseline
low/high 7 (58%)/5 (42%)
BMI
BMI30 3 (25%)
BMI 25.0–29.9 6 (50%)
BMI<25 3 (25%)
Charlson Comorbidity score
index score of 0 9 (75%)
index score of 1 3 (25%)
Agreed to muscle biopsies
yes/no 8 (67%)/4 (33%)
Days from diagnosis to radiotherapy start
mean (range) 21 (12–29)
Days from diagnosis to training start
mean (range) 23 (16–34)
BMI5body mass index; ECOG5Eastern Cooperative Oncology
Group.
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Fig. 1. Attended training sessions per patient. Each dark grey box represents one attended training session. Light grey boxes show ses-
sions not attended, whilst the cross-hatched boxes show when patients were hospitalized. Black lines show the period where each patient
was undergoing concomitant chemoradiotherapy during the training program. Right column shows number of attended sessions for each
patient, and bold writing when the patient attended at least 25 of 36 planned sessions. Sessions cancelled due to e.g., bank holidays were
rescheduled. Sessions missed for personal reasons were not.
Fig. 2. Physical tests and progression. Functional performance measured by 30-second arm curl test (A), 30-second chair stand test (B),
and stair climbing time (C). Muscle strength measured by 1RM tests in legs and chest press machines, respectively upper and lower part
of graph (D), and maximal leg extension power (E). Progression of load (weight lifted) for each exercise (leg press, back extensions, low
row, knee extensions, knee flexions, chest press, and abdominal crunches) during the 12-week program (F). A-E: Values presented as
mean6SD. Change from baseline: **p<0.01, ***p<0.001. Black line, both male and female. Dark green line, male. Light green line,
female. F: Progression presented as mean values at each training session. Grey area shows treatment period.
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the weight loss began immediately after the start of
treatment and weight declined steadily during the 6
weeks of treatment (Fig. 3B). This seemingly steady
decline masks major variance between the patients (Sup-
plementary Table S4). Mean loss of TBM at 6 weeks was
7.76 4.6 kg (range 1.9 to 15.6) (p< 0.001), equivalent to
9.16 4.8% (range 3.6 to 17.5) (p< 0.001). Most patients
continued losing weight during the training intervention
period, though not at the same speed as during treat-
ment. At the 13-week assessment, mean TBM loss was
9.06 4.9 kg (range 22.1 to 16.4) (p<0.001), equivalent
to 10.865.1% (range 23.2 to 18.7) (p< 0.001). TBM loss
peaked at the 13-week assessment but by the 13-month
follow-up TBM was partly regained and not significantly
different from baseline (Fig. 3A and Supplementary
Table S4).
Interestingly, the majority of TBM loss during
CCRT comprised of LBM loss (64%) while at the end of
the 12-week PRT only 32% of TBM loss was accounted
for by LBM (Figure 3D). Thus, LBM loss during CCRT
was 5.16 3.5 kg (range 20.3 to 11.4) (p< 0.001), equiva-
lent to 9.365.6% (range 20.8 to 20.0) (p< 0.001). At
this time point LBM was at its lowest and patients
began regaining LBM, hence the loss of LBM had
decreased and the LBM loss at the 12-week assessment
was just 3.66 2.4 kg (range 0.7 to 8.0) (p< 0.01), equiva-
lent to 6.86 3.4% (range 1.4 to 12.3) (p<0.001) (Fig. 3A
and Supplementary Table S4).
Fig. 3. Body composition, weight, and self-reported physical activity. A. Change in body composition (kg), presented as mean6SD. Mea-
sured by DXA scan at baseline, after 6 weeks (end of concomitant chemoradiotherapy [CCRT]), after 13 weeks (end of training program),
and at 5, 9, and 13-month follow-up (respectively 27, 44, and 62 weeks). Grey area shows treatment period. After CCRT, lean body mass
(LBM) began to increase, whilst fat mass (FM) continued to decline during the 12-week training program. At 13-month follow-up total body
mass (TBM), LBM, and FM had nearly reached baseline values. Change from baseline: **p<0.01, ***p<0.001 (significance level was not
analyzed at 5 and 9 months follow-up). B. Major weight loss is seen over the course of CCRT (0–6 weeks) and a continued minor loss after
CCRT. Lowest mean weight is seen at the end of the progressive resistance training program (13 weeks). Dark grey line shows mean val-
ues, colored area shows6SD, and light grey line shows the range. C. Scores from leisure time and work were added and presented as
mean6SD. When added a score from 2 to 8 was given; 2 being sedentary throughout the day, 8 being hard physical activity both at work
and during leisure time. D. Difference in composition of TBM. At the end of CCRT (week 6) the majority of TBM loss constituted of LBM
loss (64%), while at the end of the 12-week progressive resistance training (PRT) only 32% of TBM loss was accounted for by LBM.
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For FM measurements please see Supplementary
Table S4 and Figure 3A.
Baseline BMI was correlated with absolute TBM
loss at all time points. This correlation was stronger at
13-months follow-up, rs50.89, p<0.001, but evident
from the 13-week assessment, rs5 0.66, p5 0.01. There
was also a positive correlation between baseline BMI
and FM loss at 13 weeks, rs r50.81, p< 0.01, as well as
at 5 and 13 months follow-up, rs5 0.81, p< 0.001,
r50.85, p< 0.01, respectively. There was no correlation
between baseline BMI and absolute LBM loss at any
time point. Data from the 13-week assessment, i.e. after
the training intervention, is shown in Figure 4.
Muscle Biopsies
In line with the loss of LBM during CCRT, the pro-
tein abundance of sarcomeric proteins tended to
decrease during CCRT and then increase during the 12-
week PRT intervention period (not statistically signifi-
cant) (Fig. 5). The same pattern was seen in the differ-
ent types of myosin isoforms, i.e., Myosin Heavy Chain
(MyHC)-Slow (slow contraction time, low power), MyHC-
2a (moderately fast contraction time, medium power),
MyHC-2x (fast contraction time, high power), and
MyHC-2b (very fast contraction time, very high power)
(Fig. 6B). Interestingly, enzymes from the pentose phos-
phate pathway (PPP) tended to be up-regulated at week
6 compared to baseline (p< 0.01) whilst the glycolysis
pathway remained unchanged (Fig. 6A).
Blood Biochemistry
Hemoglobin, leukocytes, platelets, and plasma ions
showed characteristic changes during and after CCRT
(Supplementary Fig. S2). Plasma glucose increased sig-
nificantly over the course of treatment and dropped to
baseline values around 2-month follow-up.
Adverse Events
Treatment-related toxicities were as expected dur-
ing and after treatment (Table II). Most frequent
treatment-related toxicity reported was mucositis,
reported by all patients, 50% with grade 3. Fatigue was
also reported by all patients, though no grade 3 or 4
events. 92% of patients experienced nausea, 17% grade 3
and no grade 4. As time passed, toxicity seemed to
decline though not quite matching baseline values at 9
months. No serious adverse events were deemed related
to PRT.
Six patients were admitted to hospital due to treat-
ment complications, 3 during the treatment period, and
the others in the weeks following treatment; median
time of admission was 8 days (range 5–36). Reasons for
hospitalization were nutritional problems as a conse-
quence of pain from the irradiated mucosa. Further-
more, 3 patients were prescribed antibiotics due to
neutropenia and/or fever.
Seven patients needed a nasogastric tube for a
median duration of 33 days (range 12–75).
Questionaires
Quality of life. Global health status, emotional,
cognitive, and social functioning all appeared to decline
during the 12-week program and return to baseline val-
ues at 5-month follow-up, but noticeably, only minor
changes were reported regarding physical and role func-
tioning (Supplementary Fig. S3). It should be noted, that
no comparisons of means or change over time analyses
were performed.
Diet. Overall, patients reported marginally insuffi-
cient total energy intake compared to estimated needs
(78–98%) (Supplementary Table S4). Likewise, protein
intake ranged from 64–90% of estimated need, however
return of questionnaires on dietary intake was low
(50%).
Patient reported physical activity, labor mar-
ket affiliation and opinions on the PRT program.
Self-reported physical activity showed no significant var-
iation over 13 months (Fig. 3C). A positive correlation
between self-reported physical activity and functional
performance (p< 0.05), and muscle strength (p<0.05),
respectively, was observed.
At baseline, 8 patients worked full time, 3 part
time, and 1 had retired. During treatment and at 2-
month follow-up all patients were on full or part-time
sick leave, but at 5-month follow-up 8 patients were
working, 4 of which worked full time. At 9-month follow-
up 8 of the remaining 10 patients had returned to work,
5 at full time. At the 13-month follow-up 9 patients had
returned to work, 6 at full time.
Fig. 4. Correlation between BMI and loss of body mass. The cor-
relation between baseline BMI and loss of total body mass (TBM),
lean body mass (LBM), and fat mass (FM), respectively, after 12
weeks. Data is presented with the individual data as well as an
approximated best fitted line for visual interpretation. Baseline
BMI was correlated with loss of TBM (rs50.66; p<0.001) and FM
(rs5 0.81; p<0.001), respectively, thus, patients with the highest
baseline BMI lost the most. There was no correlation between
baseline BMI and loss of LBM.
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Fig. 5. Sarcomeric protein content in muscle. Baseline values are set to 1.0, and values are normalized accordingly. Thick filament consists
of myosin, myosin binding protein C, and titin; thin filament of actin, tropomyosin, and troponin; Z-band of myozenin, actinin, myotilin, myo-
palladin, Fhl1, and alpha-crystallin B chain; and M-band of myomesin. Protein abundance of sarcomeric proteins tends to decrease during
CCRT and increase after the 12 weeks of resistance training.
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At the end of the 12-week PRT program patients
were asked several open-labeled questions regarding
their participation in the program. In general, patients
were satisfied with the program and the time schedule.
They reported large benefits regarding social, physical,
and psychological well-being, and generally recom-
mended the program for future patients. Patients stated
for example that “this has been a lifesaver”, “made going
Fig. 6. Metabolic pathways, myoglobin, and muscle fiber types. Muscle biopsies from the four patients with the greatest difference in lean
body mass during the 12 weeks of progressive resistance training (PRT) were analyzed using mass spectrometry based proteome analysis.
A. Change in enzyme expression in the pentose phosphate pathway (PPP) and glycolysis. Enzymes from the PPP seemed to be up-
regulated at week 6 compared to baseline whilst the glycolysis pathway remained unchanged. B. Changes in myoglobin and the fiber types
of skeletal muscle were investigated. Type 1 (slow contraction time, low power), type 2a (moderately fast contraction time, medium power),
and type 2x (fast contraction time, high power), and type 2b (very fast contraction time, very high power). A1B. Baseline values are set to
1.0 and values at week 6 and 13 are normalized accordingly. Median values and upper quartiles are presented.
TABLE II.
Toxicity.
Baseline During treatment
14 days post
CCRT
2 months post
CCRT
5 months post
CCRT
9 months post
CCRT
13 months post
CCRT
(n512) (n5 12) (n5 12) (n512) (n5 12) (n5 10) (n510)
Any
grade %
Any
grade %
Any
grade %
Any
grade %
Any
grade %
Any
grade %
Any
grade %
(%) 3 and 4 (%) 3 and 4 (%) 3 and 4 (%) 3 and 4 (%) 3 and 4 (%) 3 and 4 (%) 3 and 4
PS 0 0 75.0 0 75.0 0 33.3 0 8.3 0 0 0 0 0
Fatigue 33.3 0 100.0 0 100.0 0 83.3 0 33.3 0 20.0 0 40.0 0
Nausea 0 0 91.7 16.7 50.0 8.3 33.3 0 0 0 0 0 0 0
Vomiting 0 0 66.7 0 41.7 0 0 0 0 0 0 0 0 0
Diarrhea 8.3 0 16.7 0 8.3 0 0 0 0 0 0 0 0 0
Mucositis 0 0 100.0 50.0 91.7 8.3 33.3 0 16.7 0 20 0 10 0
Constipation 0 0 75.0 0 41.7 0 8.3 0 0 0 0 0 0 0
Neuropathy (S) 0 0 16.7 0 25.0 0 16.7 0 8.3 0 40.0 0 10.0 0
Neuropathy (M) 0 0 8.3 0 8.3 0 8.3 0 0 0 0 0 10.0 0
Neutropenic fever 0 0 0 0 8.3 8.3 0 0 0 0 0 0 0 0
Fever 0 0 0 0 8.3 0 0 0 0 0 0 0 0 0
Hearing 8.3 0 25.0 8.3 16.7 8.3 8.3 8.3 8.3 8.3 10.0 10.0 10.0 10.0
Pain in throat (%) (n512) (n511) (n510) (n512) (n512) (n510) (n57)
- no pain 66.7 0 10.0 66.7 83.3 90.0 85.7
- mild pain 16.7 0 40.0 16.7 8.3 10.0 14.3
- moderate pain 16.7 9.1 20.0 8.3 9.0 0 0
- severe pain 0 90.9 30.0 8.3 8.3 0 0
Toxicities were scored according to CTCAE version 4.0 and were as expected during and after concomitant chemoradiotherapy. NRS pain scores were
grouped as follows: 0, no pain; 1–2, mild pain; 3–4, moderate pain; 5–10, severe pain. CTCAE5Common Terminology Criteria for Adverse Events; M5motor.
NRS5Numeric Rating Scale; S5 sensory.
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through treatment easier”, “when I was down and physi-
cally exhausted, working out helped me feel better and
gave me energy”, “the best that could happen in our sit-
uation.” (Supplementary Table S5).
DISCUSSION
Progressive resistance training is feasible and
appreciated by patients with stage III/IV head and neck
cancer undergoing CCRT. In addition to testing the fea-
sibility of the PRT program during treatment, this study
included a range of secondary endpoints to test the
entire setting of a PRT study, including scans, question-
naires, etc., before launching a randomized trial.
Evaluations of physical activity levels in HNSCC
survivors show that very few of these participate in
moderate or vigorous exercise, and that more than half
of them are sedentary.35 Treatment-related symptoms
are frequent barriers to exercise training,36 as these
patients are typically heavily taxed with cumulated
treatment toxicity.37 Furthermore, following radiother-
apy HNSCC survivors show lower levels of LBM, muscle
strength, and functional performance compared to
healthy individuals. Yet, one study showed that 12
weeks of PRT after treatment completion evened out the
differences.38 We hypothesized that moving PRT for-
ward, concurrent with treatment, may attenuate the
deterioration experienced during treatment and facili-
tate quicker recovery. A few studies have investigated
exercise training in HNSCC patients concurrent with
treatment.18–21 However, these trials are heterogeneous
with regard to several variables such as patient group
(radiotherapy treated only, CCRT, or mixed), interven-
tion (type, frequency, and intensity), and outcome mea-
sures (e.g., feasibility, QoL, functional performance,
fatigue) making them nearly impossible to compare,
let alone extend the results and conclude on the feasibil-
ity of a different program in another clinical setting.
Thus, before launching a larger clinical trial, we decided
to conduct a pilot study testing the feasibility of the
program.
We found that 68% (13 out of 19) of eligible patients
informed about the protocol accepted inclusion, showing
that some patients definitely are interested in conduct-
ing exercise during treatment. This was confirmed by an
adherence rate during CCRT of 93%. However, as treat-
ment progresses so does treatment side effects, and as a
consequence adherence declined during the end of the
treatment period and the weeks following, as seen in
Figure 1. As adverse events diminished, we found that
training attendance increased again. When asked, the
patients proclaimed that the training made going
through treatment easier, and helped them feel better
and more energetic, but an objective evaluation of this
was not possible as no control group was included. The
patient group is highly selected as only patients with
performance status 0–1 were included, this was prede-
termined as an inclusion criteria. Furthermore, all
patients had p16-positive oropharyngeal cancer, which
was not predetermined but a result of the patient popu-
lation in the unit and maybe also due to positive
attitude towards exercise in this head and neck cancer
population. Naturally, this limits interpretation of the
results to this group of head and neck cancer patients,
but as the incidence of HPV-related head and neck can-
cers is increasing the number of patients for whom these
criteria is applicable also increases.39,40
A particular concern in head and neck cancer
patients is weight loss. Weight loss around 10% during
treatment is not unusual and as much as 72% is consti-
tuted of LBM loss.1,4 Since depletion in muscle mass is
associated with increased risk of recurrence as well as
overall mortality,7 finding countermeasures while not
compromising safety is crucial. Data from this pilot
study does not give rise to any concerns regarding accel-
erated weight loss, with a mean weight loss of 9% after
treatment at week 6. On the contrary, while TBM and
FM loss continued after end of treatment, patients in
this study started gaining LBM immediately after treat-
ment cessation. Whether this was due to PRT is not pos-
sible to answer in this non-randomized study. Jackson
et al. have presented similar results in a study with a
subset of HNSCC patients from a larger cohort.1 Data
were pooled from controls and exercise patients and also
here, the patients regained LBM faster than TBM.
A significant increase in functional performance at
the 13-month follow-up was seen. This may be attrib-
uted to increased awareness of exercise after attending
the PRT program, but may just as likely merely reflect
that the patients are disease free and have recovered
physically following the cancer diagnosis.
In addition to the gross measure of LBM, we also
performed detailed molecular profiling of the muscular
sarcomeric protein content. The sarcomers make up the
bulk of the muscles, and comprise the contractile units
within the muscle fibers. We found that the expression
of these sarcomeric proteins followed the pattern of both
LBM and muscle strength, indicating that reductions in
LBM and muscle strength may rely not only on func-
tional deficits but also on structural changes. In addi-
tion, we evaluated expression of the different myosin
heavy chain genes. All tended to decrease in line with
the loss of muscle mass and sarcomeric protein content.
Yet, the effect was most pronounced for type 2, which
are also the fiber types, which are most readily affected
by physical inactivity and neural denervation. Moreover,
studies have shown that resistance training causes a
decrease in MyHC-2x expression and an increase in
MyHC-2a,41 which might also play a role in our study.
Interestingly, we found the pentose phosphate path-
way (PPP) seemed to be up-regulated. PPP is known to
play an important part in the anabolic metabolism of the
cells and it holds a key part in cell proliferation as it
generates ribose-5-phosphate to be used in nucleotides
and nucleic acids.42 A major product from this synthesis
is NADPH, which is essential for sequestering intracel-
lular oxidative stress. Thus, this finding might indicate
treatment-induced stress of the intramuscular signaling
pathways.
Resistance training was chosen as the exercise
modality due to superiority to aerobic exercise in induc-
ing muscle hypertrophy.22 For optimal hypertrophic
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response progression in training intensity is essential.
The data presented here shows that patients did pro-
gress during the 12-week training program in terms of
weight lifted, even during the treatment period with
heavy adverse effects. When designing exercise interven-
tions, it is important to consider essential principles of
training, i.e., individualization, specificity, progression,
and recovery.43 In this study, training was individualized
and prescribed relative to baseline muscular strength
status. Moreover, training took place at the hospital and
was coordinated with meals and treatments, and finally
patients trained every other day giving the muscles
appropriate resting periods.
The potential benefit of adding PRT to the CCRT
program can only be examined in larger and randomized
studies. In such studies, not only the nominal LBM
change but also changes in strength, functional perfor-
mance, QoL, adverse events, and dietary intake are rele-
vant in order to determine any potential benefits. This
study was merely the necessary pilot study indicating
whether a randomized trial may be possible in our clini-
cal setting. However, we can conclude that collecting
these data was feasible and the positive responses from
the patients definitely support the plan to test progres-
sive resistance training during treatment for head and
neck cancer in a randomized controlled trial.44
Recently, it was shown that loss of LBM during
treatment is associated with increased mortality,7 hence,
if resistance training can attenuate loss of LBM in these
patients it may very well positively affect long-term out-
come. That exercise to some extent can be used as medi-
cine in various diseases is beyond any doubt45 but to
what extent it is possible to change disease outcome in
head and neck cancer patients is just one of many ques-
tions within the field of exercise-oncology that must be
further elucidated.
CONCLUSION
This article shows that PRT in severely affected
patients undergoing CCRT for head and neck cancer is
not only feasible, but patients also respond favorably to
the training intervention. Of course, only a randomized
trial will be able to reveal the potential effect of PRT
during CCRT in head and neck cancer patients.
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